Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.63 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.63 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.37 |
| ▸ | FCGRT | P55899 | 1/20 | 0.37 |
| ▸ | PRLHR | P49683 | 1/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26181665 | 0.96 | KDM1A (0.66) | KDM1ARCOR1SSTR2HSP90AB1TERF2IP | |
| SCHEMBL26181682 | 0.92 | KDM1A (0.72) | KDM1ARCOR1SSTR2TERF2IPPSMB5 | |
| SCHEMBL26181706 | 0.91 | KDM1A (0.78) | KDM1ARCOR1SSTR2HSP90AB1TERF2IP | |
| SCHEMBL24451380 | 0.90 | KDM1A (0.72) | KDM1ARCOR1SSTR2TERF2IPKEAP1 | |
| SCHEMBL17882110 | 0.89 | KDM1A (0.67) | KDM1ARCOR1SSTR2TERF2IPPSMB5 | |
| SCHEMBL19386841 | 0.89 | KDM1A (0.67) | KDM1ARCOR1SSTR2TERF2IPPSMB5 | |
| SCHEMBL16426317 | 0.89 | KDM1A (0.65) | KDM1ARCOR1SSTR2TERF2IPPSMB5 | |
| SCHEMBL22520966 | 0.88 | KDM1A (0.66) | KDM1ARCOR1SSTR2TERF2IPKEAP1 | |
| SCHEMBL25623812 | 0.88 | KDM1A (0.66) | KDM1ARCOR1SSTR2TERF2IPKEAP1 | |
| SCHEMBL17882117 | 0.88 | KDM1A (0.65) | KDM1ARCOR1SSTR2TERF2IPPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | KDM1A 4789/4885RCOR1 4863/4885SSTR2 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.